Thai Professor Urges Greater, Not Less, Use Of Tamiflu For Bird Flu
This article was originally published in PharmAsia News
Executive Summary
A Thailand professor suggests healthcare providers prescribe a higher dose of Roche's Tamiflu (oseltamivir) for resistant strains of the H5N1 avian influenza virus, not avoid its use altogether. Nicholas White of Mahidol University wrote in a medical journal that despite the threat of resistance, higher doses of the drug should be used because of its fatality rate - 262 deaths out of 433 people infected since 2003. He said common sense argues for higher doses to reduce the fatality of infections. White's article drew criticism from other medical experts who said it was dangerous to rely on a single flu drug such as Tamiflu. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.